Pharmacokinetics, pharmacodynamics and food effect of LB30870, a novel direct thrombin inhibitor, after single oral doses in healthy men

References

• Camilleri M. (2006). Integrated upper gastrointestinal response to food intake. Gastroenterology 131:640–58
   PubMed Web of Science ®Google Scholar
• Carlsson SC, Mattsson C, Eriksson UG, et al. (2005). A review of the effects of the oral direct thrombin inhibitor ximelagatran on coagulation assays. Thromb Res 115:9–18
   PubMed Web of Science ®Google Scholar
• Charman WN, Porter CJH, Mithani S, Dressman JB. (1997). Physicochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J Pharm Sci 86:269–82
   PubMed Web of Science ®Google Scholar
• Choi T, Khan AI, Greilich PE, Kroll MH. (2006) Modified plasma-based ecarin clotting time assay for monitoring of recombinant hirudin during cardiac surgery. Am J Clin Pathol 125:290–5
   PubMed Web of Science ®Google Scholar
• Clement B, Kotthaus J, Kotthaus J, Schade D. (2013). Orally bioavailable dabigatran prodrugs for the treatment of diseases. US 2013/0030023 A1
   Google Scholar
• Eriksson BI, Quinlan DJ, Eikelboom JW. (2011). Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med 62:41–57
   PubMed Web of Science ®Google Scholar
• Fleisher D, Li C, Zhou, Y. (1999). Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. Clin Pharmacokinet 36:233–54
   PubMed Web of Science ®Google Scholar
• Freyburger G, Macouillard G, Labrouche S, Sztark F. (2011). Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 127:457–65
   PubMed Web of Science ®Google Scholar
• Frost C, Wang J, Nepal S, et al. (2013). Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol 75:476–87
   PubMed Web of Science ®Google Scholar
• Gustafsson D, Bylund R, Antonsson T, et al. (2004). A new oral anticoagulant: the 50-year challenge. Nat Rev Drug Dis 3:649–59
   PubMed Web of Science ®Google Scholar
• Gustafsson D, Nyström J, Carlsson S, et al. (2001). The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 101:171–81
   PubMed Web of Science ®Google Scholar
• Heimbach T, Xia B, Lin TH, He H. (2013). Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data. AAPS J 15:143–58
   PubMed Web of Science ®Google Scholar
• Kadokura T, Kashiwa M, Groenendaal D, et al. (2013). Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa nhibitor, in healthy Caucasian and Japanese subjects. Biopharm Drug Dispos 34:431–41
   PubMed Web of Science ®Google Scholar
• Lee K, Park CW, Jung WH, et al. (2003). Efficacious and orally bioavailable thrombin inhibitors based on a 2,5-thienylamidine at the P1 position: discovery of N-carboxymethyl-d-diphenylalanyl-l-prolyl[(5-amidino-2-thienyl)methyl]amide. J Med Chem 46:3612–22
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee S, Cho KH, Kim A. (2013). Pharmacokinetics and dose-dependency of LB30870 in rats, dogs, and monkeys. J Pharm Investig 43:197–203
   Google Scholar
• Lentz KA. (2008). Current methods for predicting human food effect. AAPS J 10:282–8
   PubMed Web of Science ®Google Scholar
• Liesenfeld KH, Schäfer HG, Trocóniz IF, et al. (2006). Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 62:527–37
   PubMed Web of Science ®Google Scholar
• Marsanapalle VP, Crison JR, Ma J, et al. (2009). Investigation of some factors contributing to negative food effects. Biopharm Drug Dispos 30:71–80
   PubMed Web of Science ®Google Scholar
• Nutescu E, Chuartrisorn I, Hellenbart E. (2011). Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis 31:326–43
   PubMed Web of Science ®Google Scholar
• Park HD, Lee S, Kim TH, et al. (2013). Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. Bioorg Med Chem Lett 23:4779–84
   PubMed Web of Science ®Google Scholar
• Schmidt LE, Dalhoff K. (2002). The mechanism of the food-drug interaction depends on physicochemical factors, physiological factors, compositions of foods, compositions of drugs, and combinative factors thereof. Drugs 62:1481–502
   PubMed Web of Science ®Google Scholar
• Schulman S, Crowther MA. (2012). How I anticoagulate in 2012, new and old anticoagulant agents, and when and how to switch. Blood 119:3016–23
   PubMed Web of Science ®Google Scholar
• Singh BN. (1999). Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 37:213–55
   PubMed Web of Science ®Google Scholar
• Stangier J. (2008). Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 47:285–95
   PubMed Web of Science ®Google Scholar
• Stangier J, Rathgen K, Stahle H, et al. (2007). The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 64:292–303
   PubMed Web of Science ®Google Scholar
• van Ryn J, Stangier J, Haertter S, et al. (2010). Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 103:116–127
   Web of Science ®Google Scholar
• Varma MV, Obach RS, Rotter C, et al. (2010). Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. J Med Chem 53:1098–108
   PubMed Web of Science ®Google Scholar
• Weitz JI. (2011). Factor Xa and thrombin as targets for new oral anticoagulants. Thromb Res 127:S5–12
   PubMed Web of Science ®Google Scholar
• Yang XZ, Diao XJ, Yang WH, et al. (2013). Design, synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing methyl ferulate. Bioorg Med Chem Lett 23:2089–92
   PubMed Web of Science ®Google Scholar
• Yang XZ, Yang WH, Xu YG, et al. (2012). Synthesis and antithrombotic evaluation of novel dabigatran prodrugs containing a cleavable moiety with anti-platelet activity. Eur J Med Chem 57:21–28
   PubMed Web of Science ®Google Scholar